News

Net profit of Cohance Lifesciences declined 83.77% to Rs 19.55 crore in the quarter ended March 2026 as against Rs 120.43 crore during the previous quarter ended March 2025. Sales declined 26.33% to Rs 619.12 crore in the quarter ended March 2026 as against Rs 840.42 crore during the previous quarter ended March 2025.For the full year,net profit declined 63.22% to Rs 179.23 crore in the year ended March 2026 as against Rs 487.34 crore during the previous year ended March 2025. Sales declined 13.03% to Rs 2268.55 crore in the year ended March 2026 as against Rs 2608.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales619.12840.42 -26 2268.552608.50 -13 OPM %15.9427.27 -18.8230.56 - PBDT87.65230.82 -62 423.84825.21 -49 PBT36.42176.65 -79 236.51658.41 -64 NP19.55120.43 -84 179.23487.34 -63 Powered by Capital Market - Live News

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 May 2026.

The board of Cohance Lifesciences at its meeting held on 27 April 2026 has approved the following:Noted the resignation of Vivek Sharma (DIN 08559495), as Executive Chairman and director of the Company with effect from 30 April 2026. Approved the appointment of Umang Vohra as Additional Director, designated as Chairman, and Group Chief Executive Officer with effect from 01 May 2026 and 20 May 2026 respectively.

Net profit of Cohance Lifesciences declined 76.01% to Rs 36.72 crore in the quarter ended December 2025 as against Rs 153.07 crore during the previous quarter ended December 2024. Sales declined 19.47% to Rs 544.55 crore in the quarter ended December 2025 as against Rs 676.23 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales544.55676.23 -19 OPM %17.5135.10 - PBDT92.40248.13 -63 PBT45.46204.57 -78 NP36.72153.07 -76 Powered by Capital Market - Live News

 Cohance Lifesciences announced that the US FDA conducted an inspection at the Company`s Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from 04 August 2025 to 12 August 2025. Following the inspection, a Form FDA-483 containing six observations was issued by the US FDA. Based on these observations, the USFDA classified the facility as �Official Action Indicated (OAI)� and subsequently issued a Warning Letter for the said facility. The Company is required to respond to the Warning Letter within the stipulated timelines prescribed by the US FDA and continues to engage with the regulator thereafter. The US revenues from this facility contributed less than 2% of consolidated revenues in FY25, with related EBITDA contribution below 1%. Powered by Capital Market - Live News